OBJECTIVE: The primary objective of this study is to report on the long-term efficacy and tolerability of pentosan polysulphate sodium (PPS) in patients with bladder pain syndrome (BPS). The secondary objective is to find the predictors of the long-term outcome. METHODS: This is a single institution, retrospective study. The study period was from 1994 to 2008. All patients fulfilled the clinical criteria of BPS, as suggested by European Society for the Study of Interstitial Cystitis. We included only patients with de novo BPS diagnosis and no previous PPS or other treatment. The efficacy of PPS was measured with the global response assessment scale (GRA). Patients were stratified into 2 groups based on the duration of the treatment. Group 1 took the drug for less than 12 months. Group 2 took the drug for more than 12 months. RESULTS: There were 271 patients eligible for the study. Most of the patients were female (90%), with the mean age at presentation of 45.5 years. The average duration of symptoms was 28.5 months. The mean follow-up was 22 months (range 3-130). Out of all the patients, 147 patients (54.2%) reported over 50% improvement using the GRA. The reported efficacy was higher in Group 2 (60%). Ninety-three patients (34.3%) decided to stop taking the medication for various reasons. The most common reasons to stop the medication were poor outcome (16.6% of patients) and side effects (11.1% of patients). Poor outcome was associated with nocturia, smoking and detrusor overactivity. Good outcome was associated with longer PPS intake (>12 months) and severe cystoscopic findings of glomerulation. CONCLUSION: Pentosan polysulphate sodium is an effective oral therapy to control the symptoms of BPS with good long-term efficacy and tolerability.
OBJECTIVE: The primary objective of this study is to report on the long-term efficacy and tolerability of pentosan polysulphate sodium (PPS) in patients with bladder pain syndrome (BPS). The secondary objective is to find the predictors of the long-term outcome. METHODS: This is a single institution, retrospective study. The study period was from 1994 to 2008. All patients fulfilled the clinical criteria of BPS, as suggested by European Society for the Study of Interstitial Cystitis. We included only patients with de novo BPS diagnosis and no previous PPS or other treatment. The efficacy of PPS was measured with the global response assessment scale (GRA). Patients were stratified into 2 groups based on the duration of the treatment. Group 1 took the drug for less than 12 months. Group 2 took the drug for more than 12 months. RESULTS: There were 271 patients eligible for the study. Most of the patients were female (90%), with the mean age at presentation of 45.5 years. The average duration of symptoms was 28.5 months. The mean follow-up was 22 months (range 3-130). Out of all the patients, 147 patients (54.2%) reported over 50% improvement using the GRA. The reported efficacy was higher in Group 2 (60%). Ninety-three patients (34.3%) decided to stop taking the medication for various reasons. The most common reasons to stop the medication were poor outcome (16.6% of patients) and side effects (11.1% of patients). Poor outcome was associated with nocturia, smoking and detrusor overactivity. Good outcome was associated with longer PPS intake (>12 months) and severe cystoscopic findings of glomerulation. CONCLUSION:Pentosan polysulphate sodium is an effective oral therapy to control the symptoms of BPS with good long-term efficacy and tolerability.
Authors: J Nordling; F H Anjum; J J Bade; K Bouchelouche; P Bouchelouche; M Cervigni; S Elneil; M Fall; T Hald; T Hanus; H Hedlund; G Hohlbrugger; T Horn; S Larsen; M Leppilahti; S Mortensen; M Nagendra; P D Oliveira; J Osborne; C Riedl; J Sairanen; M Tinzl; J J Wyndaele Journal: Eur Urol Date: 2004-05 Impact factor: 20.096
Authors: J Curtis Nickel; Jack Barkin; John Forrest; Phillip G Mosbaugh; J Hernandez-Graulau; David Kaufman; Keith Lloyd; Robert J Evans; C Lowell Parsons; Linda E Atkinson Journal: Urology Date: 2005-04 Impact factor: 2.649
Authors: E Rovner; K J Propert; C Brensinger; A J Wein; M Foy; A Kirkemo; J R Landis; J W Kusek; L M Nyberg Journal: Urology Date: 2000-12-20 Impact factor: 2.649
Authors: Joop P van de Merwe; Jørgen Nordling; Pierre Bouchelouche; Kirsten Bouchelouche; Mauro Cervigni; L Kurosch Daha; Suzy Elneil; Magnus Fall; Gero Hohlbrugger; Paul Irwin; Svend Mortensen; Arndt van Ophoven; John L Osborne; Ralph Peeker; Benedikte Richter; Claus Riedl; Jukka Sairanen; Martina Tinzl; Jean-Jacques Wyndaele Journal: Eur Urol Date: 2007-09-20 Impact factor: 20.096
Authors: Yik N Lim; Peter Dwyer; Christine Murray; Debjyoti Karmakar; Anna Rosamilia; Elizabeth Thomas Journal: Int Urogynecol J Date: 2016-12-16 Impact factor: 2.894
Authors: Julia B Hennermann; Seyfullah Gökce; Alexander Solyom; Eugen Mengel; Edward H Schuchman; Calogera M Simonaro Journal: J Inherit Metab Dis Date: 2016-09-02 Impact factor: 4.982
Authors: Eileen M Geoghegan; Diana V Pastrana; Rachel M Schowalter; Upasana Ray; Wei Gao; Mitchell Ho; Gary T Pauly; Dina M Sigano; Campbell Kaynor; Ellen Cahir-McFarland; Benoit Combaluzier; Jan Grimm; Christopher B Buck Journal: Cell Rep Date: 2017-10-31 Impact factor: 9.423
Authors: T Bschleipfer; R Doggweiler; D Schultz-Lampel; J de Jong; A Gonsior; J Hensen; E Heßdörfer; B T Kaftan; A Kuhn; U Kunzendorf; A Lampel; A Landmesser; A Loch; O Moormann; B Müller; J Neuhaus; A Reich; R Roth; S Schumacher; R Stratmeyer; W Vahlensieck; A Wördehoff; B Münder-Hensen Journal: Urologe A Date: 2019-11 Impact factor: 0.639